Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy
The investigators previously identified three novel HLA-A*0201 or HLA-A*0206-restricted
epitope peptides, which were derived from a cancer-testis antigen, URLC10, as targets for
cancer vaccination against lung cancer. In this phase I trial, the investigators examine
using a combination of these three peptides the safety, immunogenicity, and antitumor effect
of vaccine treatment for HHLA-A*0201 or HLA-A*0206-positive advanced non-small cell lung
cancer patients who failed to standard therapy.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluation of safety (NCI CTCAE version3): the number of adverse events of vaccination therapy.
Yataro Daigo, MD, PhD
Department of Medical Oncology, Shiga University of Medical Science
Japan: Ministry of Health, Labor and Welfare